Trial Profile

A Phase 2 Open-Label Study of PTR-01 in Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PTR 01 (Primary)
Indications Epidermolysis bullosa dystrophica
Focus Adverse reactions; Therapeutic Use
Sponsors Phoenix Tissue Repair

Most Recent Events

04 Aug 2022 According to a BridgeBio Pharma media release, positive data from this trial were shared in a poster at the Society for Investigative Dermatology (SID) Annual Meeting 2022.
20 May 2022 Results presented in the BridgeBio Pharma Media Release.
20 May 2022 According to a BridgeBio Pharma media release, data from this study are being shared in a poster at the Society for Investigative Dermatology (SID) Annual Meeting 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com